The thrombolysis in myocardial infarction (TIMI) risk score for STEMI was calculated as the sum of independent predictors of mortality and ischemic events and derived from STEMI patients in the In TIME II randomized controlled trial. The risk scores applied to patients who are treated exclusively with PPCI have shown favorable results. Thus, risk stratification prior to intervention has great clinical importance to identify patients at higher risk and to optimize their therapeutic management. However, it has been observed that the benefit of PPCI is different in each group of patients and the benefit is greatest in those at high risk. The superiority of primary percutaneous coronary intervention (PPCI) over fibrinolysis has been demonstrated in several studies. Reperfusion therapy, either pharmacological or mechanical, is indicated in patients with STEMI with duration of less than 12 h. This process also affects the development of thrombus that is superimposed on the erosion of an atherosclerotic plaque and consequently causes MI. The inflammatory process that underlines atherosclerosis has a critical role in plaque destabilization. Multiple pathophysiological factors influence this atherosclerotic process, and one of the most important factors is inflammation. Coronary atherosclerosis is the main cause of ST elevation acute myocardial infarction (STEMI). Atherosclerosis is the major cause of cardiovascular disease (CVD). Coronary artery disease (CAD) and acute myocardial infarction (MI) are a major cause of death and morbidity worldwide.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |